Shenzhen, China – February 27, 2025 – From February 25 to 27, 2025, a distinguished delegation comprising leaders from over ten prominent government and business institutions in Dubai—including Dubai’s Executive Office, Dubai Future Foundation, Dubai Municipality Head Office, and Dubai Chambers—visited Shenzhen for an innovation-focused exchange and study tour. Accompanied by Shenzhen municipal officials, the delegation explored the city’s dynamic innovation ecosystem, with a key visit to HighTide Therapeutics (2511.HK) representing the biopharmaceutical sector.
Dr. Liping Liu, CEO of HighTide Therapeutics, warmly welcomed the delegation and expressed gratitude for the continued support from the Shenzhen government. Dr. Liu led a comprehensive tour of the company’s headquarters, providing insights into HighTide’s pioneering innovations and global strategic roadmap.
During the visit, the delegation explored HighTide’s strategic exhibition area, which highlighted the company’s global footprint. As a China-rooted enterprise with a global vision, HighTide has established clinical research operations across more than 200 clinical trial centers worldwide, spanning China, the U.S., Canada, and Australia. Additionally, the company has built a robust global intellectual property portfolio. A key point of discussion was HighTide’s expert think tank—an international consortium of renowned specialists that fosters cross-border collaboration by integrating Eastern and Western expertise. This unique model of “local wisdom meets global synergy” sparked in-depth conversations, offering the delegation valuable insights into China’s innovative approach to developing global healthcare solutions.
The delegation also visited HighTide’s laboratories, where they engaged with core scientific teams and reviewed an extensive collection of research publications displayed throughout the facility. These materials showcased clinical and preclinical findings for HTD1801, HighTide’s lead candidate for metabolic disorders. Delegates expressed keen interest in the company’s scientific advancements, carefully examining its portfolio of research published in top-tier journals and presented at international conferences. Interactive discussions further facilitated knowledge exchange on key areas of mutual interest.
By the conclusion of the visit, the delegation had gained a comprehensive understanding of HighTide’s pipeline strategy and global ambitions. They praised the company’s pioneering approach—leveraging traditional Chinese natural products while achieving technological breakthroughs—as a model for global pharmaceutical innovation. The delegation noted that this approach serves as a strategic blueprint for emerging markets, including the Middle East, to participate in the evolving global pharmaceutical landscape. Expressing enthusiasm for future collaboration, the delegation reaffirmed its commitment to supporting China’s innovative therapies on the world stage.
About HighTide Therapeutics
HighTide Therapeutics, Inc. (HKEX: 2511) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional multi-targeted therapies with poly-indications across metabolic and digestive diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for metabolic dysfunction-associated nonalcoholic steatohepatitis (MASH), type 2 diabetes mellitus (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). Berberine ursodeoxycholate (HTD1801), the company’s lead drug candidate, received Fast Track designation from the U.S. FDA for both MASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.
For more information, please visit www.hightidetx.com.
Contact: pr@hightidetx.com